PENELOPE-B Final Analysis: Palbociclib Shows No Survival Benefit in High-Risk HR+/HER2- Breast Cancer
EU Approves Enhertu for HR-Positive, HER2-Low, HER2-Ultralow Metastatic Breast Cancer Following Endocrine Therapy
Interim SERENA-6 Data: Camizestrant Significantly Improves PFS in First-Line HR+/HER2- Advanced Breast Cancer With ESR1 Mutations